Delta-Fly Pharma Inc.: Update for Development Status of DFP-17729
4.12.2024 13:00:00 EET | Business Wire | Press release
We are excited to share our latest development status.
We are pleased to announce that as a result of consultation with the PMDA on December 3rd, 2024, the Phase II/III clinical trial of DFP-17729 in combination with TS-1 versus TS-1 alone in patients with pancreatic cancer after third-line treatment was approved.
In a Phase I/II study of DFP-17729 in combination with TS-1 in patients with end-stage pancreatic cancer, no significant difference was observed against the control treatment (TS-1 or gemcitabine), but stratified analysis showed that when patients in the third-line or later treatment were treated for more than 6 weeks, DFP-17729 in combination with TS-1 showed a predominant median overall survival (mOS) prolongation (9.0 months vs. 6.1 months) and a significant correlation was also observed between urinary alkalinization and mOS in pancreatic cancer patients treated with DFP-17729, as key proof of concept. We had presented these results at the ESMO Gastrointestinal Cancers Congress 2024 and the 55 Annual Meeting of the Japan Pancreas Society, where much attention was paid to the presentation.
DFP-17729 is a novel approach to neutralize the acidic cancer microenvironment, and several patents on related inventions have been granted in major countries around the world, and its potential of efficacy has been published in peer-reviewed journals.
We will first identify DFP-17729 as a treatment for refractory pancreatic cancer, for which effective treatment is not yet available, and then seek to expand the indication to other types of cancer through partnership with major global pharmaceutical companies.
Please take notice of our own innovative approach for miserable cancer patients and contact us.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241204497142/en/
Contacts
Inquires
Yasundo Yamasaki, Ph.D.
Director, Business Development
Delta-Fly Pharma Inc.
Head office: Tokushima 771-0117, Japan
Phone: +81-3-6231-1278
E-mail: yyamasaki1206@delta-flypharma.co.jp
Home page: https://www.delta-flypharma.co.jp/en/ -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.delta-flyp
harma.co.jp%2Fen%2F&esheet=54161588&newsitemid=20241204497142&lan=en-US&anchor=h
ttps%3A%2F%2Fwww.delta-flypharma.co.jp%2Fen%2F&index=1&md5=adcd527d539f6849e5052
6d1e02039b2
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Gurobi Defines Its Role as the Technology Behind Better Decisions in the AI Era7.4.2026 16:00:00 EEST | Press release
Gurobi Optimization, LLC, the leader in decision intelligence technology, today announced a renewed brand identity that reflects its role in empowering organizations to make better decisions in complex, high-stakes environments. As organizations increasingly rely on optimization to put their AI-driven insights into action, the Gurobi Optimizer is a foundational component of decision intelligence systems, where different approaches to AI—from prediction to optimization—work together to guide business outcomes. “AI has transformed how organizations generate insight, but insight alone does not drive outcomes—decisions do,” said Duke Perrucci, CEO, Gurobi. “We see optimization as the GPS for AI, enabling users to determine the best possible course of action in complex environments. Those decisions are what drive real outcomes, and we’re proud to be the technology behind them.” Across industries such as energy, supply chain management, manufacturing, and finance, organizations trust Gurobi
Poland's Galaxy Systemy Informatyczne Becomes First Private Enterprise to Buy Quantum Computer from IQM7.4.2026 16:00:00 EEST | Press release
IQM Quantum Computers, a global leader in superconducting quantum computing, today announced a commercial milestone to deploy a hybrid integrated quantum computer at GalaxySystemy Informatyczne Sp. z o.o., marking its first deployment in a private enterprise worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407351934/en/ IQM Radiance quantum computer Galaxy has been implementing innovations in security, digitisation, and hardware infrastructure while providing IT solutions, supporting HPC infrastructure to shape Poland’s economy based on data and artificial intelligence. The 54-qubit Radiance system will also be the most advanced quantum computer in Poland, and Galaxy, a provider of technological solutions, will become the first private company in the world to own and operate such quantum infrastructure. The system, which will be installed at Galaxy’s headquarters in Zielona Góra in the fourth quarter of 2026, wil
Cessna SkyCourier Strengthens Mission Versatility With New In‑Flight Operable Door Option7.4.2026 16:00:00 EEST | Press release
Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company, today announced a new In-Flight Operable Door option for the passenger variant of its twin-engine, large-utility Cessna SkyCourier turboprop, expanding the aircraft’s Special Mission versatility for military, humanitarian and commercial operations. The functionality is expected to be available as a Special Mission factory-installed option in 2028. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407228562/en/ Mission flexibility starts at the Cessna SkyCourier door “An In-Flight Operable Door builds on the Cessna SkyCourier’s reputation for reliability and adaptability, reinforcing its role as a purpose-built solution for high-demand missions,” said Bob Gibbs, vice president, Special Missions Sales. “The option opens new opportunities for customers worldwide, including armed forces, smokejumpers, disaster relief groups and commercial skydiving operators.” The Cessna
Peruvian Army Selects Beechcraft King Air 360C for Multi-Mission Operation7.4.2026 16:00:00 EEST | Press release
The Peruvian Army has signed an agreement to purchase a cargo door equipped Beechcraft King 360C aircraft, which is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company, to deliver critical services for communities across the country. With its generous payload, the twin-engine turboprop will enhance the Army’s capability to perform medical evacuations, transport patients and provide rapid humanitarian aid during disaster relief efforts. The aircraft is expected to enter service in 2028. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260407176246/en/ Beechcraft King Air 360C supporting the Peruvian Army’s emergency response, medical evacuation and disaster relief missions This order follows the delivery of two multi-mission, air medical equipped Beechcraft King Air 360CHW aircraft to the Peruvian Air Force. The King Air 360CHW is cargo door equipped and fitted for operation at higher operating
Variational AI Releases Enki 4: Major Update to Foundation Model for Small-Molecule Drug Discovery7.4.2026 16:00:00 EEST | Press release
Variational AI today announced the release of Enki™ 4, a major update to its generative AI platform for small-molecule drug discovery. The release of the fourth generation of Enki™ delivers significant improvements in algorithmic performance and target coverage through platform architecture design, as well as extending its application to degraders, PROTACs, glues, and novel payload design for antibody drug conjugates (ADCs) and related modalities. “Enki 4 is a massive step forward for our platform,” said Ali Saberali, Co-Founder & Head of Platform at Variational AI. “We’ve re-architected Enki and improved the underlying algorithms to expand target and modality coverage, while operating faster to deliver even better performance for our partners.” Enki 4 now supports the rapid generation of novel, potent, selective, and synthesizable lead-like structures pre-trained on 760 drug targets, a 28% increase over the previous Enki version’s 592 targets, with more to be released soon. The update
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom